iECURE
Kimberly M. Smith, CPA, CGMA, is an accomplished financial professional with extensive experience in accounting and finance roles across various organizations. Currently serving as the Founder of Controllership Accounting and Advisory Services, PLLC since May 2023, Kimberly has held significant positions including VP of Finance and Accounting at iECURE, inc. since September 2021, and previously as Managing Director of Controllership Advisory Services at Genova Group. Other notable roles include VP of Finance and Corporate Controller at Tmunity Therapeutics Incorporated, VP of Corporate Accounting/Controller at Fibrocell, and interim Manager of Global Consolidations at ViroPharma. Kimberly's career began with audits at Ernst & Young, LLP and has progressed through various strategic finance positions at reputable companies. Kimberly holds a Bachelor of Science in Business and Economics with a major in Accounting from Lehigh University College of Business.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.